Wound botulism in injection drug users: time to antitoxin correlates with intensive care unit length of stay
- PMID: 20046244
- PMCID: PMC2791728
Wound botulism in injection drug users: time to antitoxin correlates with intensive care unit length of stay
Abstract
Objectives: We sought to identify factors associated with need for mechanical ventilation (MV), length of intensive care unit (ICU) stay, length of hospital stay, and poor outcome in injection drug users (IDUs) with wound botulism (WB).
Methods: This is a retrospective review of WB patients admitted between 1991-2005. IDUs were included if they had symptoms of WB and diagnostic confirmation. Primary outcome variables were the need for MV, length of ICU stay, length of hospital stay, hospital-related complications, and death.
Results: Twenty-nine patients met inclusion criteria. Twenty-two (76%) admitted to heroin use only and seven (24%) admitted to heroin and methamphetamine use. Chief complaints on initial presentation included visual changes, 13 (45%); weakness, nine (31%); and difficulty swallowing, seven (24%). Skin wounds were documented in 22 (76%). Twenty-one (72%) patients underwent mechanical ventilation (MV). Antitoxin (AT) was administered to 26 (90%) patients but only two received antitoxin in the emergency department (ED). The time from ED presentation to AT administration was associated with increased length of ICU stay (Regression coefficient = 2.5; 95% CI 0.45, 4.5). The time from ED presentation to wound drainage was also associated with increased length of ICU stay (Regression coefficient = 13.7; 95% CI = 2.3, 25.2). There was no relationship between time to antibiotic administration and length of ICU stay.
Conclusion: MV and prolonged ICU stays are common in patients identified with WB. Early AT administration and wound drainage are recommended as these measures may decrease ICU length of stay.
Similar articles
-
Early diagnosis and critical management of wound botulism in the emergency department: a single center experience and literature review.Int J Emerg Med. 2021 Sep 22;14(1):56. doi: 10.1186/s12245-021-00375-4. Int J Emerg Med. 2021. PMID: 34551726 Free PMC article.
-
Infant botulism: a 30-year experience spanning the introduction of botulism immune globulin intravenous in the intensive care unit at Childrens Hospital Los Angeles.Pediatrics. 2007 Dec;120(6):e1380-5. doi: 10.1542/peds.2006-3276. Pediatrics. 2007. PMID: 18055655
-
Emergency Department Length of Stay for Critical Care Admissions. A Population-based Study.Ann Am Thorac Soc. 2016 Aug;13(8):1324-32. doi: 10.1513/AnnalsATS.201511-773OC. Ann Am Thorac Soc. 2016. PMID: 27111127
-
In-Hospital Outcomes in Patients Admitted to the Intensive Care Unit after a Return Visit to the Emergency Department.Healthcare (Basel). 2021 Apr 7;9(4):431. doi: 10.3390/healthcare9040431. Healthcare (Basel). 2021. PMID: 33917232 Free PMC article.
-
Medical treatment for botulism.Cochrane Database Syst Rev. 2014 Feb 20;(2):CD008123. doi: 10.1002/14651858.CD008123.pub3. Cochrane Database Syst Rev. 2014. Update in: Cochrane Database Syst Rev. 2019 Apr 17;4:CD008123. doi: 10.1002/14651858.CD008123.pub4 PMID: 24558013 Updated. Review.
Cited by
-
Exposure-Response Modeling and Simulation to Support Human Dosing of Botulism Antitoxin Heptavalent Product.Clin Pharmacol Ther. 2022 Jul;112(1):171-180. doi: 10.1002/cpt.2620. Epub 2022 May 16. Clin Pharmacol Ther. 2022. PMID: 35467014 Free PMC article.
-
Wound Botulism Among Persons Who Inject Black Tar Heroin in New Mexico, 2016.Front Public Health. 2021 Dec 16;9:744179. doi: 10.3389/fpubh.2021.744179. eCollection 2021. Front Public Health. 2021. PMID: 34976915 Free PMC article. Review.
-
Early diagnosis and critical management of wound botulism in the emergency department: a single center experience and literature review.Int J Emerg Med. 2021 Sep 22;14(1):56. doi: 10.1186/s12245-021-00375-4. Int J Emerg Med. 2021. PMID: 34551726 Free PMC article.
-
Wound Botulism in Black Tar Heroin Injecting Users: A Case Series.J Investig Med High Impact Case Rep. 2021 Jan-Dec;9:23247096211028078. doi: 10.1177/23247096211028078. J Investig Med High Impact Case Rep. 2021. PMID: 34259080 Free PMC article.
-
Wound Botulism Caused by Botulinum Neurotoxin Type A in a Chronic Parenteral Drug Abuser.Case Rep Neurol. 2020 Nov 12;12(3):422-427. doi: 10.1159/000510846. eCollection 2020 Sep-Dec. Case Rep Neurol. 2020. PMID: 33362521 Free PMC article.
References
-
- Centers for Disease Control and Prevention: Botulism in the United States 1899–1996 . Handbook for epidemiologists, clinicians, and laboratory workers. Atlanta, GA: Centers for Disease Control and Prevention; 1998.
-
- Centers for Disease Control and Prevention Emergency Preparedness & Response Botulism: October62006. Available at: http://www.bt.cdc.gov/agent/botulism/. Accessed March 30, 2009.
-
- Cherrington M. Botulism: update and review. Semin Neurol. 2004;24:155–63. - PubMed
-
- Werner SB, Passaro D, McGee J, et al. Wound botulism in California, 1951–1998: Recent epidemic in heroin injectors. CID. 2000;31:1018–24. - PubMed
-
- Passaro DJ, Werner SB, McGee J, et al. Wound botulism associated with black tar heroin among injecting drug users. JAMA. 1998;279:859–63. - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous

